Allergy Therapeutics plc (LON:AGY – Get Free Report) shares were up 9.7% during trading on Wednesday . The company traded as high as GBX 6 and last traded at GBX 5.90. 595,174 shares were traded during mid-day trading, an increase of 120% from the average daily volume of 270,738 shares. The stock had previously closed at GBX 5.38.
Allergy Therapeutics Trading Up 1.7%
The company has a market cap of £350.19 million, a price-to-earnings ratio of -5.70, a price-to-earnings-growth ratio of -30.70 and a beta of 0.87. The business’s fifty day moving average price is GBX 7.33 and its 200 day moving average price is GBX 9.59. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
